200 related articles for article (PubMed ID: 12797451)
1. Viral vectors for dendritic cell-based immunotherapy.
Humrich J; Jenne L
Curr Top Microbiol Immunol; 2003; 276():241-59. PubMed ID: 12797451
[TBL] [Abstract][Full Text] [Related]
2. Viral vectors for dendritic cell-based immunotherapy.
Jenne L; Schuler G; Steinkasserer A
Trends Immunol; 2001 Feb; 22(2):102-7. PubMed ID: 11286712
[TBL] [Abstract][Full Text] [Related]
3. Transduction of dendritic cells by antigen-encoding lentiviral vectors permits antigen processing and MHC class I-dependent presentation.
Zarei S; Leuba F; Arrighi JF; Hauser C; Piguet V
J Allergy Clin Immunol; 2002 Jun; 109(6):988-94. PubMed ID: 12063529
[TBL] [Abstract][Full Text] [Related]
4. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials.
Mossoba ME; Medin JA
Expert Rev Vaccines; 2006 Oct; 5(5):717-32. PubMed ID: 17181444
[TBL] [Abstract][Full Text] [Related]
6. Interaction of large DNA viruses with dendritic cells.
Jenne L; Thumann P; Steinkasserer A
Immunobiology; 2001 Dec; 204(5):639-48. PubMed ID: 11846229
[TBL] [Abstract][Full Text] [Related]
7. Review: dendritic cell immunotherapy for melanoma.
Hadzantonis M; O'Neill H
Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation.
Steinman RM
Mt Sinai J Med; 2001 May; 68(3):160-6. PubMed ID: 11373688
[TBL] [Abstract][Full Text] [Related]
9. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity.
He Y; Zhang J; Mi Z; Robbins P; Falo LD
J Immunol; 2005 Mar; 174(6):3808-17. PubMed ID: 15749922
[TBL] [Abstract][Full Text] [Related]
10. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.
Herrera OB; Brett S; Lechler RI
Vaccine; 2002 Dec; 21(3-4):231-42. PubMed ID: 12450698
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
12. Genetic modification of dendritic cells and its application for cancer immunotherapy.
Nishioka Y; Hua W; Nishimura N; Sone S
J Med Invest; 2002 Feb; 49(1-2):7-17. PubMed ID: 11901764
[TBL] [Abstract][Full Text] [Related]
13. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
[TBL] [Abstract][Full Text] [Related]
14. Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy.
Ponnazhagan S; Mahendra G; Curiel DT; Shaw DR
J Virol; 2001 Oct; 75(19):9493-501. PubMed ID: 11533211
[TBL] [Abstract][Full Text] [Related]
15. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
[TBL] [Abstract][Full Text] [Related]
16. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells.
Lizée G; Gonzales MI; Topalian SL
Hum Gene Ther; 2004 Apr; 15(4):393-404. PubMed ID: 15053864
[TBL] [Abstract][Full Text] [Related]
17. The interaction of immunodeficiency viruses with dendritic cells.
Steinman RM; Granelli-Piperno A; Pope M; Trumpfheller C; Ignatius R; Arrode G; Racz P; Tenner-Racz K
Curr Top Microbiol Immunol; 2003; 276():1-30. PubMed ID: 12797441
[TBL] [Abstract][Full Text] [Related]
18. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells.
Schnell S; Young JW; Houghton AN; Sadelain M
J Immunol; 2000 Feb; 164(3):1243-50. PubMed ID: 10640737
[TBL] [Abstract][Full Text] [Related]
19. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma.
Su H; Li B; Zheng L; Wang H; Zhang L
Oncotarget; 2016 Jul; 7(30):48401-48411. PubMed ID: 27351282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
